Lupin is currently trading at Rs 487.45, up by 4.85 points or 1.00% from its previous closing of Rs 482.60 on the BSE.
The scrip opened at Rs 486.65 and has touched a high and low of Rs 492.00 and Rs 484.30 respectively. So far 1,21,331 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 519.80 on 30-Nov-2010 and a 52 week low of Rs 363.00 on 25-Feb-2011.
Last one week high and low of the scrip stood at Rs 492.00 and Rs 469.50 respectively. The current market cap of the company is Rs 21547.94 crore.
The promoters holding in the company stood at 46.96% while Institutions and Non-Institutions held 42.76% and 10.28% respectively.
Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc. (LPI) has been granted final approval by the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to market a generic version of Watson’s NOR-QD tablets. The company will commence shipping its norethindrone tablets, USP 0.35 mg shortly.
NOR-QD (norethindrone tablets, USP 0.35 mg) is a progestin-only oral contraceptive indicated for the prevention of pregnancy. Combined annual sales for NOR-QD and its generic equivalents were approximately $52 million for the twelve months ended June 2011 based on IMS Health sales data.
Recently, Lupin Pharmaceutical Inc (LPI) had been granted final approval by the US Food and Drug Administration (FDA) for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of UCB’s Keppra XR tablets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |